Sangamo announces positive preliminary data from phase 1/2 Alta study evaluating SB-52
Sangamo Therapeutics announced positive preliminary data from the Phase 1/2 clinical trial evaluating SB-525, a cDNA gene therapy candidate for Hemophilia A (the "Alta study"). SB-525 is being developed as part of a global collaboration between Sangamo and Pfizer. August 09, 2018